



Viyash Scientific Limited

(Formerly known as Sequent Scientific Limited)

Registered Office:

3rd Floor, Srivalli's Corporate, Plot No.290, Road No.6,
Sy.No.33, 34P to 39, Guttala Begumpet, Jubilee Hills,
Hyderabad, Shaikpet, Telangana, India-500033

T: +91 40 23635000, E:info@viyash.com

E: investorrelations@sequent.in

Website: www.sequent.in

CIN: L99999TS1985PLC196357

February 06, 2026

To,

BSE Limited

Corporate Relationship Department

Phiroze Jeejeebhoy Towers,

Dalal Street, Fort,

Mumbai – 400 001

National Stock Exchange of India Limited

Listing Department

Exchange Plaza, Bandra-Kurla Complex,

Bandra (East),

Mumbai – 400 051

Scrip code: 512529

Symbol: VIYASH

Subject: Investor Presentation for Q3 FY 2025-26

Dear Sir/ Madam,

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Investor Presentation on Unaudited Standalone and Consolidated Financial Results for the quarter ended December 31, 2025.

This is for your information and appropriate dissemination.

You are requested to take the same on record.

Yours faithfully,

For **Viyash Scientific Limited**

(Formerly known as Sequent Scientific Limited)

Yoshita Vora

Company Secretary & Compliance Officer

Encl: A/a



INVESTOR PRESENTATION

Q3 FY26


VIYASH SCIENTIFIC LIMITED

February 06, 2026

"We mark a significant milestone today, announcing results of the merged entity for first time. The results of Q3FY25-26 are an indication of the actions we have taken and the momentum we have built across the last few quarters, working as one team. Revenue, margins, profitability all have continued to show strong growth on the back of new product introductions, cost improvement and synergies across our business units. We have a strong balance sheet and market position and are geared up for capturing the market opportunity in the next 3-5 years. The merger is starting to generate benefits across R&D, manufacturing and front-end, all of which make us very excited for the journey ahead."

Dr Hari Babu Bodepudi
Viyash Scientific Limited

Q3FY26 Financial Snapshot



Viyash Scientific: Q3 FY26 Performance Highlights

All values in ₹ Mn

Revenues



₹8,584
Million

+11 %
YoY

EBITDA¹



₹1,854
Million

+64%
YoY

EBITDA margin



21.6%

+690 bps
YoY

Net Debt to LTM EBITDA¹



0.4x

**1.2x in Q3
FY25**

Viyash Scientific: 9M FY26 Performance Highlights

All values in ₹ Mn

Revenues



₹25,004
Million

+12 %
YoY

EBITDA¹



₹5,024
Million

+58 %
YoY

EBITDA margin



20.1%

+580 bps
YoY

Net Debt to LTM EBITDA¹



0.4x

**1.2x in 9M
FY25**

Viyash Scientific: Broad based revenue growth across all businesses


All values in ₹ Mn

Revenue Distribution	Q3 FY26	Q3 FY25	YoY Gr%	Q2 FY26	QnQ Gr%	9M FY26	9M FY25	YoY Gr%
Formulations	4,809	4,009	20%	4,687	3%	13,666	11,934	15%
Europe	1,790	1,334	34%	1,520	18%	4,949	4,250	16%
Emerging Markets	1,630	1,366	19%	1,469	11%	4,580	3,713	23%
India	401	308	30%	362	11%	1,025	893	15%
USA	988	1,001	-1%	1,337	-26%	3,112	3,079	1%
APIs	3,658	3,556	3%	3,721	-2%	11,071	10,098	10%
Other Sales	85	110		62		239	257	
Global Sales	8,552	7,675	11%	8,470	1%	24,976	22,289	12%
One Offs [#]		-		-		(56)	(74)	
Adjustment* - Ind AS 29*	33	65		33		84	130	
Reported Sales	8,584	7,740	11%	8,503	1%	25,004	22,345	12%


* Adjustment on account of hyperinflation in Turkey as per Ind AS 29. # Provision for customer claim on shipments in prior years

Sustained Sales Growth with Consistent EBITDA Expansion


Sales




Gross Margin



EBITDA*



Net Debt to LTM EBITDA



Viyash Consolidated Financials


All values in ₹ Mn

Particulars	Q3 FY26	Q3 FY25	Grw YoY %	Q2 FY26	Grw QnQ %	9M FY26	9M FY25	Grw YoY %
Revenue from Operations	8,584	7,740	10.9%	8,503	1.0%	25,004	22,345	11.9%
Material Consumption	(3,909)	(3,770)		(3,785)		(11,499)	(11,054)	
Gross Margin	4,675	3,971	17.7%	4,718	-0.9%	13,505	11,291	19.6%
% Gross margin	54.5%	51.3%		55.5%		54.0%	50.5%	
Employee Benefit Expenses	(1,298)	(1,309)	-0.9%	(1,292)	0.4%	(3,848)	(3,683)	4.5%
Operating Expenses	(1,532)	(1,517)	0.9%	(1,588)	-3.5%	(4,690)	(4,406)	6.4%
Exchange Gain / (Loss)	8	(16)		45		57	(23)	
EBITDA*	1,854	1,127	64.4%	1,883	-1.6%	5,024	3,179	58.0%
% EBITDA	21.6%	14.6%		22.1%		20.1%	14.2%	
ESOP cost	(79)	(135)		(100)		(309)	(462)	
Exceptional Items	(413)	(29)		(17)		(442)	(72)	
IndAS 29 Adjustment	(5)	5		(7)		25	23	
Other Income	127	67		31		220	227	
Finance Cost	(168)	(206)		(175)		(547)	(657)	
Depreciation	(585)	(584)		(591)		(1,732)	(1,740)	
Earnings Before Tax	731	245	198.0%	1,024	-28.6%	2,238	498	349.0%
% Earnings before Tax	8.5%	3.2%		12.0%		9.0%	2.2%	
Taxes**	(246)	175		(295)		(655)	(19)	
Earnings After Tax	485	420	15.5%	729	-33.5%	1,583	480	230.0%


- +10.9% YoY in Q3 sales with 320 bps gross margin improvement
- Finance cost reduction on account of the run-down of the debt
- Exceptional items (Total INR 413 Mn):
 - Stamp duty (INR 296 Mn)
 - Merchant banking (INR 91 Mn)
 - Other professional expenses (INR 26 Mn)
- **One time MAT credit reversal impact in tax (INR 77 Mn)

*EBITDA adjusted for ESOP

Business Update



Formulation business – Key Pillars of success (1/2)




Formulation business – Key Pillars of success (2/2)



API business – Key Pillars of success

R&D led portfolio expansion	Network Optimization	Business Development	New business segments
<ul style="list-style-type: none"> ✓ Rapid new product launches giving a competitive offering to the market ✓ Identified opportunistic products to enter 	<ul style="list-style-type: none"> ✓ Cost optimization through process improvements and backward integration 	<ul style="list-style-type: none"> ✓ Focused on high end markets ✓ Cross sell of products 	<ul style="list-style-type: none"> ✓ Expanding lines of business through CDMO development

Key updates from Q3 FY26



Facility Inspections

- ✓ **3** Regulatory Audits
- ✓ **45** Customer audits



Regulatory Approvals

- ✓ **5 APIs:** (USDMF-2 ; EDQM-2; KDMF-1)



Launches

- ✓ **5 APIs**



Products Filed

- ✓ **9 Filings** – SFDA(3), EDQM (1) TGA (1), EDMF (2), WHO (1), TW (1)



Validations Completed


- ✓ **3 APIs**



R&D Pipeline

- ✓ **17** Products

Our vision and strategy



Our focus areas

Companion Animals



- Signed exclusive distribution agreement with Boehringer Ingelheim for companion animal products in India
- Building new products to deepen presence in existing markets and open new markets
- Exploring partnerships and M&A opportunities
- Build manufacturing infrastructure in India

Farm Animals



- Geo extension: launching existing products across all core and new markets
- Filling gaps in the product portfolio to establish dominance in the markets
- Expanding into new markets

Human Health



- Leveraging manufacturing in India for mature products
- Develop complex generics including integrated oncology portfolio

API + CDMO



- Focus on CDMO opportunities
- Early development of complex products
- Leverage existing capacity

"One R&D"



250

Membered R&D team


- Implemented for integrated product development
- Containment facility for finished product development
- Expanding team and capability to handle complex products

Market Opportunity (1/2): Growing generics market in Animal Health, especially Companion Animals

There are two large strategic growth levers

Increasing pet ownership

Which is a fast growing, profitable segment and overlaps with human treatments




Market size (\$ Bn)

Farm Animals Companion Animals



Genericization of animal health

Which currently lags compared to human health



Penetration of generics

These trends require strong R&D and manufacturing capabilities to capitalize on these trends; Viyash poised to capture these trends

Market Opportunity (2/2): API patent cliff and CDMO opportunities


Two mega trends in the API + CDMO segment

2025-2030 patent cliff: Large number of APIs coming off patent



Increasing competence of India to win CDMO contracts

- ~190+ patents coming to the market with an estimated opportunity of ~\$250bn-300bn
- This includes 60+ blockbuster products with annual sales exceeding \$1bn



CDMO market size in India (\$Bn)

India is well poised to disproportionately benefit because of these factors:

- Operational experience in complex manufacturing
- China +1 diversification by global innovators
- Cost advantage

“One R&D”: Scaled our R&D capabilities to drive product led innovation



Scaled

- 200+ members (including 20+ PhDs)
- 20 fully equipped self sufficient analytical laboratories
- R&D group dedicated for support to CMO/CDMO partners



Technically Strong


- Dedicated lab for handling cytotoxic products
- Proven capability to handle Iron complex, Inorganic products, Complex molecules
- Fully equipped dedicated Process Safety Lab



Delivering Results

- Our efforts over the last years have now started reflecting in our strong financials

Combined API Manufacturing Network : 10 facilities with global approvals




10 manufacturing plants in AP and Maharashtra



Plant	Unit	Capacity (KL)	Focus	US FDA	EU GMP	WHO GMP	KFDA	ANVISA	PMDA
Viyash	Unit 1	39	API / HP API	✓	✓	✓	✓		✓
	Unit 2	296	API/ HP API	✓	✓	✓		✓	
	Unit 3	80	API	✓	✓	✓	✓	✓	
	Unit 4	454	API	✓	✓	✓			
	Unit 5	137	API	✓	✓		✓	✓	
	Unit 6	487	API+Advanced Intermediates	✓		✓		✓	
	Unit 7	255	Advanced Intermediates	✓					
	Unit 8	413	Advanced Intermediates	✓					
	Unit 9 (AH)	80	API		✓	✓			
Alivira Vizag	(AH)	290	API	✓		✓			

Merger Update



Merger process status update

- Merger has been approved by all regulatory authorities, and the merger is in effect
- **Focus on synergy realization for next 12 months**
- **The process is well on track as per estimated timelines**





Area	Key Ideation Action Items	Progress
R&D	<ul style="list-style-type: none"> R&D teams to be co-located; to work collaboratively on NPD & cost improvement QA & Testing to be moved on-site from 3rd party location 	<ul style="list-style-type: none"> API R&D fully integrated leading to accelerated development 4 New animal health products developed/validated 3 Cost improvement projects completed Regulatory filing in progress
Manufacturing	<ul style="list-style-type: none"> Utilize available low-cost capacity through the group; action plan created Procurement synergies identified 	<ul style="list-style-type: none"> 6 Intermediates validated at Viyash sites, which were procured from external sources New production block created and got EU approval; commercialization already started One large volume Sequent API validated & filing under progress
Sales	<ul style="list-style-type: none"> Leverage key relationships of both companies; outreach & discussion plan prepared 	<ul style="list-style-type: none"> Business teams working closely to identify opportunities to cross sell
Others	<ul style="list-style-type: none"> Assess shared administrative & support functions 	<ul style="list-style-type: none"> All support functions' integration initiated

For details, feel free to contact:

Yoshita Vora


Company Secretary

 +91 22 4111 4777

 investorrelations@sequent.in

Abhishek Singhal

Investor Relations Consultant

 abhishek@arunya.co.in

Registered Office: Plot No.290, Srivalli's Corporate, Road No.6, Kakatiya Hills, Madhapur Hyderabad Rangareddy TG 500081, India

Websites: www.viyash.com | CIN: L99999TS1985PLC196357 | BSE Code:512529 | NSE: VIYASH

ISIN: INE807F01027

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. SeQuent Scientific Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.



Thank You